Revenue remains highly erratic, moving from near-zero levels around $72K through most of 2024 and early 2025 to $70.6M in 2025Q3 and $25.8M in 2026Q3, while operating margin stayed deeply negative at -4.0% to -1,303.7% across the period, showing that milestone timing rather than product demand drives reported results.
Viridian Therapeutics, Inc. (VRDN) annual income statement — 14-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 26.31M | 70.85M | 302K | 314K | 1.77M | 2.96M | 1.05M | 4.46M | 8.39M | 4M | 3.34M | 2.54M | 4.32M | 4.32M | 4.41M |
| Revenue Growth % | -62.83% | 23359.93% | -3.82% | -82.28% | -40.2% | 182.19% | -76.46% | -46.8% | 109.49% | 19.96% | 31.48% | -41.25% | 0.08% | -2.03% | - |
| Cost of Goods Sold | 1.85M | 0 | 0 | 0 | 0 | 0 | 28.3M | 0 | 30.42M | 19.62M | 2.55M | 2.47M | 3.24M | 2.5M | 3.04M |
| COGS % of Revenue | - | - | - | - | - | - | 2695.62% | - | 362.76% | 490.21% | 76.36% | 97.4% | 75.07% | 57.89% | 69.05% |
| Gross Profit | 24.46M | 70.85M | 302K | 314K | 1.77M | 2.96M | -27.25M | 4.46M | -22.04M | -15.62M | 789K | 66K | 1.08M | 1.82M | 1.36M |
| Gross Margin % | 92.98% | 100% | 100% | 100% | 100% | 100% | -2595.62% | 100% | -262.76% | -390.21% | 23.64% | 2.6% | 24.93% | 42.11% | 30.95% |
| Gross Profit Growth % | - | 23359.93% | -3.82% | -82.28% | -40.2% | 110.87% | -710.94% | 120.25% | -41.07% | -2079.72% | 1095.45% | -93.87% | -40.74% | 33.26% | - |
| Operating Expenses | 493.13M | 434.24M | 299.34M | 254.76M | 136.08M | 82.69M | 83.13M | 46.44M | 41.47M | 30.54M | 10.46M | 11.25M | 8.04M | 2.26M | 4.46M |
| OpEx % of Revenue | - | 612.91% | 99118.21% | 81135.03% | 7679.23% | 2790.79% | 7916.76% | 1041.02% | 494.51% | 762.8% | 313.55% | 443.38% | 186.2% | 52.44% | 101.19% |
| Selling, General & Admin | 184.94M | 95.31M | 61.08M | 95M | 35.18M | 25.8M | 13.27M | 11.65M | 11.05M | 10.91M | 9.57M | 10.25M | 7.75M | 2.17M | 4.23M |
| SG&A % of Revenue | - | 134.53% | 20226.16% | 30254.46% | 1985.44% | 870.91% | 1263.33% | 261.06% | 131.76% | 272.6% | 286.93% | 403.9% | 179.42% | 50.2% | 96.08% |
| Research & Development | 308.51M | 338.93M | 238.25M | 159.76M | 100.89M | 56.89M | 28.3M | 34.79M | 30.42M | 19.62M | 888K | 1M | 293K | 96.85K | 225.38K |
| R&D % of Revenue | - | 478.38% | 78892.05% | 50880.57% | 5693.79% | 1919.88% | 2695.62% | 779.96% | 362.76% | 490.21% | 26.61% | 39.48% | 6.78% | 2.24% | 5.12% |
| Other Operating Expenses | -320K | 0 | 0 | 0 | 0 | 0 | 41.56M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -468.66M | -363.39M | -299.04M | -254.45M | -134.3M | -79.73M | -110.38M | -41.98M | -33.08M | -26.53M | -12.51M | -11.19M | -6.87M | -196.21K | -4.03M |
| Operating Margin % | -1781.38% | -512.91% | -99018.21% | -81035.03% | -7579.23% | -2690.79% | -10512.38% | -941.02% | -394.51% | -662.8% | -374.83% | -440.78% | -158.96% | -4.55% | -91.4% |
| Operating Income Growth % | - | -21.52% | -17.52% | -89.46% | -68.45% | 27.77% | -162.94% | -26.89% | -24.69% | -112.12% | -11.81% | -62.91% | -3399.77% | 95.13% | - |
| EBITDA | -467.96M | -362.94M | -298.5M | -253.93M | -134.05M | -79.61M | -110.14M | -41.69M | -32.8M | -26.22M | -12.17M | -11M | -6.72M | -47.9K | -3.88M |
| EBITDA Margin % | -1778.71% | -512.27% | -98839.4% | -80868.79% | -7564.84% | -2686.74% | -10489.62% | -934.57% | -391.16% | -655.11% | -364.61% | -433.53% | -155.63% | -1.11% | -88.12% |
| EBITDA Growth % | -42.82% | -21.59% | -17.55% | -89.43% | -68.39% | 27.72% | -164.18% | -27.1% | -25.09% | -115.53% | -10.58% | -63.66% | -13936.08% | 98.77% | - |
| D&A (Non-Cash Add-back) | 701K | 460K | 540K | 522K | 255K | 120K | 239K | 288K | 281K | 308K | 341K | 184K | 144K | 148.31K | 144.29K |
| EBIT | -435.47M | -337.65M | -266.9M | -235.89M | -129.39M | -79.41M | -40.52M | -41.04M | -31.83M | -26.13M | -12.58M | -11.19M | -6.87M | -197K | -4.03M |
| Net Interest Income | 6.04M | 22.45M | 29.09M | 16.72M | 4.43M | 315K | -335K | 106K | 381K | 20K | -95K | -141K | -1.02M | -1.96M | -1.59M |
| Interest Income | 33.69M | 27.4M | 32.13M | 18.56M | 4.92M | 318K | 173K | 941K | 1.25M | 403K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 27.65M | 4.95M | 3.05M | 1.85M | 486K | 3K | 508K | 835K | 873K | 383K | 95K | 141K | 1.02M | 1.96M | 1.59M |
| Other Income/Expense | 15.08M | 20.79M | 29.09M | 16.72M | 4.43M | 315K | -335K | 106K | 381K | 20K | -166K | -141K | -1.02M | -1.71M | -1.59M |
| Pretax Income | -453.58M | -342.6M | -269.95M | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M | -32.7M | -26.51M | -12.67M | -11.33M | -7.89M | -2.16M | -5.62M |
| Pretax Margin % | -1724.06% | -483.56% | -89387.09% | -75711.46% | -7329.23% | -2680.16% | -10544.29% | -938.65% | -389.97% | -662.3% | -379.8% | -446.34% | -182.64% | -50.03% | -127.51% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 95K | 95K | 0 | 0 | 1.96M | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.36% | -0.75% | 0% | 0% | -90.91% | 0% |
| Net Income | -453.58M | -342.6M | -269.95M | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M | -32.7M | -26.51M | -12.67M | -11.33M | -7.89M | -2.16M | -7.21M |
| Net Margin % | -1724.06% | -483.56% | -89387.09% | -75711.46% | -7329.23% | -2680.16% | -10544.29% | -938.65% | -389.97% | -662.3% | -379.8% | -446.34% | -182.64% | -50.03% | -163.67% |
| Net Income Growth % | -50.21% | -26.91% | -13.55% | -83.05% | -63.54% | 28.27% | -164.41% | -28.04% | -23.35% | -109.18% | -11.88% | -43.57% | -265.33% | 70.05% | - |
| Net Income (Continuing) | -453.58M | -342.6M | -269.95M | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M | -32.7M | -26.51M | -12.67M | -11.33M | -7.89M | -2.16M | -5.62M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.00 | -3.32 | -3.98 | -5.31 | -3.91 | -6.66 | -31.20 | -20.31 | -16.57 | -20.66 | -17.57 | -21.00 | -52.46 | -11.48 | -38.75 |
| EPS Growth % | -19.08% | 16.58% | 25.05% | -35.81% | 41.29% | 78.65% | -53.62% | -22.57% | 19.8% | -17.59% | 16.33% | 59.97% | -356.97% | 70.37% | - |
| EPS (Basic) | - | -3.32 | -3.98 | -5.31 | -3.91 | -6.66 | -31.20 | -20.31 | -16.57 | -20.66 | -17.57 | -21.00 | -52.46 | -11.48 | -38.75 |
| Diluted Shares Outstanding | 113.41M | 84.8M | 67.89M | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 1.97M | 1.28M | 721.41K | 539.46K | 150.39K | 188.12K | 186.09K |
| Basic Shares Outstanding | 113.41M | 84.8M | 67.89M | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 1.97M | 1.28M | 721.41K | 539.45K | 150.39K | 188.12K | 186.09K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying VRDN stock.
For fiscal year 2025, Viridian Therapeutics, Inc. (VRDN) reported total revenue of $70.8M. This represents a 1508.0% increase compared to $4.4M in 2012.
Viridian Therapeutics, Inc. (VRDN) reported a net loss of $342.6M for the fiscal year ending 2025.
Viridian Therapeutics, Inc. (VRDN) reported an operating income of $-363.4M, resulting in an operating profit margin of -512.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Viridian Therapeutics, Inc. (VRDN) generated $70.8M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Cash runway vs Phase 3 funding
Metrics are mathematically derived from official filings.
Lumpy Revenue Masks Persistent Burn Trend
According to reported quarterly figures, VRDN revenue swung from $70.6M in 2025Q3 to $25.8M in 2026Q3 after sitting near $72K for most of 2024 and early 2025, a pattern driven by milestone timing rather than product demand.
The sequence of near-zero quarters followed by single large receipts suggests revenue reflects licensing and milestone events instead of a recurring commercial base. Because the operating loss persisted through the revenue spikes, investors should treat headline growth rates as distorted by a small denominator. The durability of this top line remains unestablished until product-level sales can be separated from one-time receipts.
Gross Margin Reflects Milestone Accounting
Based on reported figures, VRDN's gross margin printed at 94.1% in 2026Q3 and 100% in several quarters, yet operating margin stood at -4.0% and -444.6% in the same window, showing gross margin carries little analytical weight here.
Gross margin is high because milestone revenue carries negligible cost of goods, not because the company has demonstrated pricing power. Without a manufacturing and distribution cost base, the metric cannot be benchmarked against commercial peers such as Red Violet's 83.7%. Investors should look past gross margin to the operating line until product COGS become observable.
Operating Loss Scales With R&D Spend
As reported in financial statements, VRDN's R&D expense rose from $56.2M in 2024Q2 to $89.2M in 2025Q4 while operating losses widened from $72.2M to $122.7M, indicating negative operating leverage.
Operating loss has grown in step with R&D rather than with revenue, which is the expected pattern for a company funding late-stage trials. SG&A also climbed from $14.4M to $57.6M over the period, implying commercial-launch preparation costs are now entering the cost base. Operating leverage will not turn positive until revenue becomes recurring and scalable relative to this fixed spend.
Stock Compensation Dominates Loss Quality
Based on EDBL's reported figures, the question for VRDN is how much of its net loss reflects cash burn versus non-cash charges, with stock-based compensation reaching $30.4M in 2026Q2 against a net loss of $127.1M.
Stock-based compensation has risen substantially over the period, which lowers the cash-burn portion of the reported loss but adds dilution cost to shareholders. Reported EPS of -0.81 to -1.23 per quarter is not meaningful for valuation until the revenue base stabilizes. Investors should assess net loss alongside SBC and share count growth rather than in isolation.
Burn Rate Threatens Trial Funding Path
Based on reported figures, VRDN's operating losses of roughly $100M to $125M in recent quarters, against a stated cash position near $212M, suggest limited headroom for Phase 3 completion without further capital raises.
If quarterly burn persists near recent levels, the cash balance could be consumed within a few quarters, raising the probability of dilutive equity financing. Lumvoa's early launch commentary may help, but the absence of disclosed EPS and guidance limits confidence that commercial revenue will offset the spend. This warrants close monitoring of the next filing for runway guidance.